Ikarian Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Ikarian Capital’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-78,550	Closed	-$1.07M	–	188
2022 Q1	$1.07M	Buy	78,550 +3,990	+5%	+$64.5K	0.14%	96
2021 Q4	$1.47M	Sell	74,560 -25,000	-25%	-$588K	0.22%	83
2021 Q3	$3.2M	Sell	99,560 -440	-0.4%	-$14.6K	0.23%	100
2021 Q2	$3.39M	Hold	100,000	–	–	0.27%	86
2021 Q1	$3.76M	Hold	100,000	–	–	0.13%	150
2020 Q4	$3.32M	Buy	+100,000	New	+$4.05M	0.15%	121

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ikarian Capital's PHAT Position: Q2 2022 in Review

Ikarian Capital sold out of Phathom Pharmaceuticals (PHAT) in Q2 2022, closing a stake of 78,550 shares — an estimated $1.07M sold.

Ikarian Capital first reported a position in PHAT in Q4 2020 and held it in 6 quarters. The position peaked at $3.76M in Q1 2021. 94 funds tracked by Wall St. Rank hold PHAT as of Q2 2022.

Ikarian Capital reported no remaining Phathom Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 78,550 Phathom Pharmaceuticals shares in Q2 2022, an estimated $1.07M.
Ikarian Capital first reported a position in Phathom Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Ikarian Capital's Phathom Pharmaceuticals position peaked at $3.76M in Q1 2021.
94 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.